Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Hisamitsu Seeks Label Expansion for Fentos Tape to Pediatric Cancer Pain
September 11, 2020
- MSD Files Keytruda for MSI-H Colorectal Cancer
September 11, 2020
- RegeNephron, Kirin Join Hands on Cell Therapy Process Development
September 10, 2020
- Takeda to Divest Non-Core Products Sold in Europe, Canada to Cheplapharm
September 10, 2020
- Japan Ethical Drug Sales Down 4.9% in July: Crecon
September 9, 2020
- SymBio Setting Up Standalone Sales System for Treakisym in Japan
September 9, 2020
- Eisai Succeeds Parkinson’s Disease Med Equfina from Meiji Pharma on Sept. 23
September 8, 2020
- Keytruda Returns to Top Spot After 2 Months in August Sales Ranking: Encise
September 7, 2020
- Akebia/Otsuka’s HIF-PH Inhibitor Vadadustat to Be Filed in US in Early 2021
September 7, 2020
- AstraZeneca Launches Japan PI/II Study of COVID-19 Vaccine; Submission Could Be Possible Based on Results
September 7, 2020
- Blackstone Setting Sights on IPO of Takeda Consumer Healthcare Within 5-10 Years
September 4, 2020
- Kyowa Kirin/Sandoz’s Rituxan Biosimilar Approved for Chronic Idiopathic Thrombocytopenic Purpura
September 4, 2020
- US Launch of Takeda’s Entyvio SC to Be Pushed Back to 2022
September 4, 2020
- Flawed Testing at Kyowa CritiCare Costs 2 More Product Recalls
September 4, 2020
- Aspen Japan Completes Takeover of Marketing Authorization, Distribution Rights for Lexotan
September 3, 2020
- Mitsubishi Tanabe to Develop Mobile App for Depression Treatment
September 3, 2020
- LTL Pharma to License Dellegra AG to Nichi-Iko, Eyeing December Rollout
September 3, 2020
- Mitsubishi Tanabe’s HIF-PH Inhibitor Hit by Shortage Days after Launch on Better-than-Expected Demand
September 2, 2020
- Janssen Launches Japan PI Study for Coronavirus Vaccine
September 2, 2020
- Gilead Revises Veklury Label Warning of Coadministration with Hydroxychloroquine or Chloroquine
September 2, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…